Wall Street analysts predict that OPKO Health, Inc. (NASDAQ: OPK) will report earnings of ($ 0.03) per share for the current quarter, according to Zacks Investment Research. Three analysts provided revenue estimates for OPKO Health. The highest EPS estimate is ($ 0.02) and the lowest ($ 0.03). OPKO Health reported earnings per share of $ 0.05 in the same quarter last year, which would suggest a negative year-over-year growth rate of 160%. The company is expected to release its next earnings report on Thursday, February 17.
According to Zacks, analysts expect OPKO Health to report annual profit of $ 0.04 per share for the current year, with EPS estimates ranging from $ 0.02 to $ 0.04. For the next fiscal year, analysts predict the company will post earnings of $ 0.03 per share, with EPS estimates ranging from $ 0.00 to $ 0.06. Zacks EPS Averages is an average based on a survey of analysts who cover OPKO Health.
OPKO Health (NASDAQ: OPK) last released its quarterly earnings data on Thursday, October 28. The biotech company reported earnings per share of $ 0.04 for the quarter, beating the consensus estimate of ($ 0.01) by $ 0.05. OPKO Health had a net margin of 4.06% and a return on equity of 4.42%. The company posted revenue of $ 385.80 million for the quarter, compared to analysts’ expectations of $ 302.27 million. In the same quarter of the previous year, the company posted earnings per share of $ 0.04. OPKO Health’s revenue for the quarter was down 9.9% year-on-year.
OPK has been the subject of a number of analyst reports. Barrington Research reiterated a “buy” note and issued a price target of $ 6.00 on OPKO Health shares in a research report on Monday, September 27. Piper Sandler reaffirmed a “buy” note and issued a target price of $ 5.00 on OPKO Health shares in a report released on Friday, September 24.
Separately, CEO Phillip Md Et Al Frost acquired 100,000 shares of the company in a transaction that took place on Tuesday, September 14. The shares were purchased at an average price of $ 3.46 per share, for a total value of $ 346,000.00. Following the completion of the purchase, the CEO now directly owns 3,068,951 shares of the Company, valued at $ 10,618,570.46. The purchase was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 41.47% of the company’s shares.
Institutional investors have recently increased or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. increased its holdings of OPKO Health shares by 5.2% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 58,060 shares of the biotech company valued at $ 212,000 after purchasing an additional 2,854 shares during the period. CIBC Asset Management Inc increased its holdings in OPKO Health by 11.4% during the 3rd quarter. CIBC Asset Management Inc. now owns 28,189 shares of the biotech company valued at $ 103,000 after purchasing an additional 2,883 shares in the last quarter. Shell Asset Management Co. increased its stake in OPKO Health by 5.7% in the second quarter. Shell Asset Management Co. now owns 58,940 shares of the biotech company valued at $ 239,000 after purchasing an additional 3,190 shares in the last quarter. Advisor Group Holdings Inc. increased its stake in OPKO Health by 1.8% in the second quarter. Advisor Group Holdings Inc. now owns 199,350 shares of the biotech company valued at $ 812,000 after purchasing an additional 3,605 shares in the last quarter. Finally, Capital Advisors Inc. OK increased its stake in OPKO Health by 2.4% during the second quarter. Capital Advisors Inc. OK now owns 168,625 shares of the biotech company valued at $ 683,000 after purchasing an additional 4,000 shares in the last quarter. Institutional investors hold 27.51% of the company’s shares.
OPKO Health shares traded down $ 0.11 on Friday, reaching $ 3.86. 5,190,678 shares of the company traded hands, compared to its average volume of 4,907,762. The company’s 50-day simple moving average is $ 3.91 and its 200-day simple moving average is $ 3.80. The company has a current ratio of 1.97, a quick ratio of 1.57, and a debt ratio of 0.11. The company has a market cap of $ 2.63 billion, a P / E ratio of 35.09 and a beta of 1.70. OPKO Health has a minimum of $ 3.26 over 12 months and a maximum of $ 6.27 over 12 months.
OPKO Health Company Profile
OPKO Health, Inc, is a biopharmaceutical and diagnostic company, which provides healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes BioReference’s clinical laboratory operations, as well as point-of-care operations.
Read more: Options trading
Get a Free Copy of Zacks’ Research Report on OPKO Health (OPK)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in OPKO Health now?
Before you consider OPKO Health, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and OPKO Health was not on the list.
While OPKO Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here